SynthesisFrontiers in pharmacology2025
Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rutin alleviates heat stress-induced intestinal oxidative damage in broilers via AMPK/PINK1-Parkin signaling pathway.Poultry science · 2026Article
- Evaluation of Phytochemical Constituents, Antioxidant Potential, and Toxicological Profile of Selected Medicinal Plants from Romania's Spontaneous Flora.Molecules (Basel, Switzerland) · 2026Article
- Drimiopsis maculata methanol extract attenuates inflammation in experimental rat model of polyarthritis: a biochemical and molecular insight.Inflammopharmacology · 2026Article
- Box-Behnken Design Optimization of Green Extraction from Tomato Aerial Parts and Axillary Shoots for Enhanced Recovery of Rutin and Complementary Bioactive Compounds.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel disease (IBD) is a chronic, potentially carcinogenic condition with limited treatment options. Rutin may represent a novel approach to treating IBD. Our aim is to conduct a systematic review of rutin, summarize its preclinical effects, demonstrate its efficacy, and provide guidance for future research. Methods: To systematically evaluate the effectiveness and feasibility of rutin in the treatment of inflammatory bowel disease (IBD) based on published experiments. A literature search up to 2023 on rutin's effects in IBD was conducted using PubMed, Embase, and Web of Science. Three independent assessors ensured objectivity by selecting and evaluating study quality and extracting data. A meta-analysis was performed using Review Manager 5.3 and STATA 17.0, combining results for a robust evaluation of rutin's efficacy in IBD treatment. Results: The meta-analysis includes nine animal studies with a total of 174 animals. The findings from these studies indicate that rutin has a significant positive impact on various indicators of intestinal disease caused by IBD. Key results include: reduced weight loss, lower disease activity index (DAI), decreased inflammatory markers, reduced oxidative stress markers, increased antioxidant defenses. Its mechanism of action involves anti-inflammatory, antioxidant, inhibition of inflammatory signaling pathways, barrier protection, inhibition of adaptive immune responses, restoration of intestinal permeability, and regulation of microbiota. Discussion: Preclinical evidence suggests that rutin can significantly alleviate the abnormal indicators of intestinal inflammation. In experiments, the performance of rutin in various indicators is very close to existing positive control drugs such as sulfasalazine and budesonide, with similar therapeutic effects. Taken together, this meta-analysis reveal that rutin has the potential to be a feasible drug for the treatment of IBD. Systematic Review Registration: CRD42024519891.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.